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Abstract: Pharmaceutical nanotechnology has generated breakthrough developments in improving health care
and human life from its emergence. The biomaterials employed mainly aim at improving drug delivery systems,
imaging and diagnostic technologies while the nanoscale materials are in widespread use in other industries such
as electronics and optics. Such advancement may revolutionize the drug development and therapy with new and
more efficient treatments. Although, nanotechnology assists humankind in improving its well being, it has certain
limitations that entail thorough investigation by the regulatory and scientific authorities. To address concerns
regarding the safety and toxicity profile of the nanopharmaceuticals, we have reviewed the challenges and solutions of
nanopharmaceuticals use in human health and the related health risks. In this regard, regulatory and scientific bodies
such as countries’ Food and Drug Administration (FDA), Organization for Economic Co-operation and Development
(OECD), European Medicine Agency (EMA), Environmental Protection Agency (EPA), National Institute for Occupational
Safety and Health (NIOSH), and World Health Organization (WHO) can participate in developing and reinforcing safety
measures and regulatory frameworks to insure the public health. The regulatory authorities may enforce the
nanopharmaceutical industries to conduct comprehensive toxicity tests and monitor the adverse drug reaction reports
in close collaboration with the scientific community to act accordingly and inform the public as the implementation of
the strategy.
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Introduction
Pharmaceutical nanotechnology deals with the scope of
pharmaceutical compounds that emerge from a multi-
disciplinary field of science entailing the development
and application of molecular structures with dimensions
smaller than 100 nm [1]. The nanoscale feature of these
products and devices render them special capabilities
that can be used to produce devices and products as
therapeutic agents and other purposes [1, 2]. Pharma-
ceutical nanotechnology has generated breakthrough
developments in health care and human life [3]. The
biomaterials employed in this field mainly aim at
improving drug delivery systems, imaging and diagnostic
technologies while the nanoscale materials are of wide-
spread use in other industries such as electronics and
optics [4]. In 1995 with the approval of Doxil® (liposomal
doxorubicin) by the US FDA, the pharmaceutical nano-
technology passed its first evolutionary milestone with
the subsequent approval of other products but the
approvals are in their early stage with less than 50 US
FDA approved drug formulations while more are in the
pipeline [1, 5, 6]. However, nanotechnology applications
in the treatment of some of most critical metabolic and
genetic diseases and cancer, delivery systems, genetic
tests, as well as imaging and diagnostics are promising
enough to absorb huge amounts of investment into re-
search and development efforts both in the academia
and the industry [1, 4, 5]. Noteworthy, nanotechnology
provides humankind with exceptional opportunities to
improve its wellbeing, but it also has certain limitations
that entail thorough investigation by the regulatory and
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scientific authorities [6, 7]. The present study reviews
the literature on the pharmaceutical application of nano-
materials and then raises the question regarding the pos-
sible health risks associated with nanopharmaceuticals
use in humans. Concerns about human use of nanoma-
terials become overwhelming when we know that these
nanostructures do not completely abide by the scientific
principles that form the basis for our knowledge about
how human physiologic system deals with exogenous
compounds and toxicity tests also fail to adequately ad-
dress the nanotoxicity issues for human beings, animals
and the environment. Moreover, the research strives to
bring the toxicological aspect of nanopharmaceuticals
and pending health risks to top agenda in regulatory
bodies as well as scientific community.
Nanopharmaceuticals: advantageous applications
and toxicological concerns
Liposomes, niosomes, polymer based micelles, nano-
structured vaccines, polymersomes, dendrimeric nano-
structures are nanoparticulate structures used as novel
and targeted drug delivery systems. These nanostruc-
tures have special structural and functional capabilities
and aspects that offers specific applications when
engineered like the composition and percentage of
components, size distribution and physical structure. In
the sense, the nanoparticles could be responsive to the
environment, targeted or assume other specificities [8, 9].
Special characteristics of nanostructures make them
useful agents for both diagnosis and imaging agents
(Fig. 1) [10]. Nanochips and nanoarrays employ different
Fig. 1 Schematic representations of some nanomaterials with pharmaceutical applications (by AuSbj (Own work) [CC BY-SA 4.0 (http://creativecommons.org/
licenses/by-sa/4.0) (https://commons.wikimedia.org/wiki/File%3ANanomaterials_enhanced_SPR.png)], via Wikimedia Commons) within the micro and macro
size range (by Sureshbup (http://www.mdpi.com/1422-0067/15/5/7158) [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia
Commons and SLN by Andrea Trementozzi (Own work) [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0) (https://commons.wikimedia.
org/wiki/File%3ASolidLipidNanoparticle.jpg)], via Wikimedia Commons)
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methods to measure various biomarkers within biologic
samples to monitor disease formation and progression.
Moreover, nanotheranostics contain both diagnostic and
pharmacotherapeutic agents in one formulation to attain
various purposes. They may be aimed at drug delivery,
drug release, drug efficacy and therapeutic drug moni-
toring. In addition, different nanoparticles have been de-
veloped to improve the diagnostic capabilities of nuclear
magnetic resonance imaging (Fig. 2) [11, 12].
With all the features in mind, there are certain concerns
with regards to nanoparticulate structure for human use
[13]. Nanoparticles toxicity has attracted the most vital
criticism because they represent exceptional characteristics
such as size, size distribution, surface charge and properties,
expanded surface area, self-assembly and stability [4].
These features influence the nanoparticles’ ADME
(Adsorption, Distribution, Metabolism and Excretion)
properties like cellular uptake, distribution within the
body fluids, and transport through biological barriers. For
instance, the tiny molecular size of the nanoparticles en-
ables them to cross the natural biological barriers in the
brain and eye or other cells. Route of administration also
determines the toxicity profile to a lesser extent as for
example, nanopharmaceuticals may trigger neurotoxicity
and inflammatory responses or even the systemic circula-
tion when applied in inhalation forms through their
penetration into the CNS via posterior nasal mucosal layer
[14]. However, our knowledge is yet scant enough not to
be sure about the mechanistic toxicology of nanoparticles
since the currently available toxicity tests are not fully
assuring and data obtained from in vitro or animal studies
are not always extrapolatable to human [15, 16].
Exposure to nanopharmaceuticals may affect manufactur-
ing personnel, healthcare professionals and the patients.
However, when the nanopharmaceuticals are disposed or
excreted via waste water, the general public will also be at
exposure. Therefore, elaborate monitoring systems based
on physicochemical characterization are required [1, 15].
As the nanoparticles enter the body, they penetrate the
epithelial and endothelial barriers and then undergo
cellular uptake processes like diffusion, different endo-
cytosis pathways such as receptor mediated endocytosis
dictated by their physicochemical and surface proper-
ties. Then their biodistribution also follows relatively
unknown patterns rather than those of other conven-
tional pharmaceuticals, though such organ deposition
in the Central Nervous System (CNS) and growing
fetus would be of dramatic concern along with other
organs like liver, kidney and spleen. Although nano-
pharmaceuticals cytotoxicity mechanisms are not well
defined, but oxidative stress, proinflammatory effects
and genotoxicity are theocratized via Reactive Oxygen
Species (ROS) formation, GSH/GSSG ratio alteration,
upregulation of transcription factors and signaling ki-
nases, DNA damage and mutation [1, 17]. Cytotoxicity
and genotoxicity have been seen with nanodrugs con-
taining metallic ions like aluminum oxide, gold, copper
oxide, silver, zinc oxide, titanium oxide, iron oxide and
carbon based nanomaterials. Although silica and poly-
mer based nanomaterials have been deemed to be more
Fig. 2 Applications of nanomaterials as (A) MRI contrast agents adapted from Wikimedia Commons [by Hellerhoff (own work); CC BY-SA 3.0
(http://creativecommons.org/licenses/by-sa/3.0) (https://commons.wikimedia.org/wiki/File%3ABluthirnschranke_nach_Infarkt_nativ_und_KM.png)],
via Wikimedia Commons), (B) drug delivery targeting using antibody (by Gerry Shaw [GFDL (http://www.gnu.org/copyleft/fdl.html) or CC BY-SA
3.0 (http://creativecommons.org/licenses/by-sa/3.0) (https://commons.wikimedia.org/wiki/File%3AHeLa_cells_stained_with_antibody_to_
actin_(green)_%2C_vimentin_(red)_and_DNA_(blue).jpg)], via Wikimedia Commons), (C) novel drug delivery devices (by National Health
Federation [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0) (https://commons.wikimedia.org/wiki/File%3ATransdermal_microneedles.
png)], via Wikimedia Commons) and (D) treatment optimization by developing marker based cell characterization (by Nima Aghaeepour et al.
[Public domain], via Wikimedia Commons (https://commons.wikimedia.org/wiki/File%3AFlowType-RchyOptimyx.png))
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biocompatible and relatively nontoxic, they may also in-
volve ROS formation and cytotoxicity [9]. Some toxicity
tests have been proposed for the nanopharmaceuticals
before their approval both in vitro and in vivo. In vitro
tests may include but not limited to uptake and transport
characterization, cytotoxicity assays (Lactate Dehydro-
genase, tetrazolium, Alamar Blue, OECD developed
Neutral Red dye assays that are based upon Neutral Red
dye cellular uptake), genotoxicity (Ames test, comet
assay, micronucleus and chromosomal aberration assays)
and carcinogenotoxicity (SHE test, BALB/c 3 T3 and
C3H10T1/2 assays). Validated in vivo tests should include
at least ADME studies and acute and chronic organ tox-
icity tests; however, these in vivo tests are time and cost
consuming and entail ethical compromises [1, 9, 18].
OECD guidelines provide a wealth of technical documents
for the toxicity testing of nanomaterials, but the OECD is
yet developing the standard materials critical for the test-
ing, working on the development of carcinogenotoxicity
tests like SHE test, BALB/c 3 T3 and C3H10T1/2 assays.
The OECD guideline for the tests on routine chemicals
are useful in this regard to some extent, but they need
more detailed discussion on the biohazards and physico-
chemical characterizations [1].
Regulatory framework for nanopharmaceuticals
Concerns regarding the safety and toxicity profile of the
nanopharmaceuticals involve active participation of regu-
latory and scientific bodies, including but not limited to
FDA, EMA, EPA, NIOSH, WHO to develop and reinforce
safety measures and regulatory frameworks to insure the
public health [7, 19].
In this venue, scientific associations as well as the
scientific committees within regulatory authorities like
US FDA and EMA release technical documents and rec-
ommendations for the industry and regulators that lead
mostly the evaluation and approval of the products and
devices as per the postulation of the public health and
quality of life. US FDA has recently updated its regulatory
approach to the nanopharmaceuticals through guidelines
and denoted that for products that contain nanoscale
materials or properties attributable to the dimensions,
may require premarket review or where not applicable,
urges the industry to consult the FDA very early in the
product development phase to address the product’s
regulatory status and concerns with regards to its
safety, effectiveness or public health impact [20]. More-
over, the FDA declared its regulatory policy towards the
nanopharmaceuticals earlier. It stated that the body
would be scientifically focused on the product filing
and applies for premarket review or consultation ap-
proach as per the rules and regulations. The FDA
already keeps the industry responsible for its products
meet all the legal requirements like safety, effectiveness
and other product quality attributes. Nevertheless, the au-
thority continues to run post-market monitoring surveys
to protect the consumers while maintaining its role in pre-
paring technical documents and advisory guidelines [21].
The bioequivalent versions of the nanotechnology derived
products or nanosimilars compose a new era of extensive
regulatory burden. In addition, regulatory authorities of
other countries have to keep in pace with the market
trend and mobilize their capacities for the oncoming
nanosimilars. Overall, the nanoparticulate biomaterials
such as liposomes and dendrimers involve more elaborate
investigations caused by their modified formulations and
ADME [3, 22].
Nanopharmaceuticals approval should contain close
characterization of physicochemical properties as they
have size and size distribution that may increase the
chance of thromboembolic complications via facilitating
the thrombosis cascade. On the other hand, nanophar-
maceuticals require sophisticated stability and ADME
studies because most of the critical parameters of their
safety and efficacy may evade during shelf life and cause
morbidities and fatalities. Moreover, FDA has approved
some liposomal, dendrimer based, PEGylated and albu-
min bound compounds while the overwhelming number
of candidates are on their way to market [23–26].
It should not be forgotten that discovery of new medi-
cines has been always expensive, time-consuming, com-
petitive, with unknown outcome to pass all preclinical
and clinical phases of approval. Therefore, to reduce the
attrition rate in further steps, investigators must pay
enough attention to safety of medicines, development
risks, dose ranging, early proof of concept/principle, and
patient stratification based on biologically and/or clinic-
ally validated biomarkers [27].
Future prospects of nanopharmaceuticals in
human health
With the advent of nanosized structures and their spe-
cial characteristics, many fields of science started to take
advantage of these extraordinarily modifiable and func-
tional features based on their special needs. Medical and
pharmaceutical experts also employed these capabilities
to develop new drugs, medical devices and therapeutic
methods. Cancer is a major cause of mortality and
morbidity that has benefited from nanopharmaceuticals
and promising progress is also on the way. In spite of
the currently approved drugs for cancer chemotherapy,
there are more than twenty candidates in clinical trials
for approval process. These candidates either improve
therapeutic/toxicity profile of existing drugs or contain
novel molecules [28, 29]. Dermatology is also applying
nanostructures for different diseases treatment because
of the special structure of skin and natural barriers that
could be simply overcome through noninvasive methods
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using the nanosized structures [30]. Drug delivery sys-
tem, nanotherapeutics, nanobots, nanoshells, nanotubes,
gene therapy, and vaccination and immunization im-
provement rank among the functional structures that
pharmaceuticals will borrow from nanotechnology while
chip technology, quantum dots and sensor nanobots
emerge advantageous for diagnostic purposes [31, 32].
However, reconstructive medicine and tissue engineering
look forward to applying nanotechnology to cover the
gap in clinical practice by providing biodegradable and
biocompatible tissues [33]. Radiation enhancers are also
under investigation to increase the usability of radiother-
apy in war against cancer [34]. Personalized medicine is
the other field of interdisciplinary medical science that is
enjoying the nanomaterials like theranostics and data
management to improve patient care based on certain
patient’s needs, genetic and health status [35].
Concluding remarks
In conclusion, it should be stated that nanopharmaceuti-
cals may pave the way for new therapies for unmet med-
ical needs and optimization of the existing therapies
with their promising features. But, in the meanwhile
their limitations should also be considered since adverse
events may come out during their use in the populations
with metabolic variations as well as health status. The
nanodrugs modified biokinetics necessitate well estab-
lished toxicology profiling through in vitro and especially
in vivo tests since the lab tests mostly cover their tox-
icity in cell lines with different physiological properties
rather than the healthy people and patients. The test
endpoints may include oxidative stress burden, inflam-
matory system, genotoxicity, carcinogenicity, respiratory,
cardiovascular, central and peripheral nervous system,
hematopoietic and lymphatic system, developmental and
reproductive toxicity. To achieve this goal, validated and
standard test protocols as well as reference standards
seem critical. Nonetheless, Quality by Design (QbD)
approach adopted by the FDA gains importance to
manufacture nanodrugs in reliable and reproducible pro-
cesses. Therefore, it would be advisable for the regula-
tory authorities to enforce the nanopharmaceutical
industries to conduct comprehensive toxicity tests and
monitor the adverse drug reaction reports closely to act
accordingly and inform the public. Proper collection of
possible toxicities and adverse events from the medical
and public community is recommended.
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